Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper Session 1

220 - Phase 1 Study of Bispecific HER2 Antibody-Drug Conjugate MEDI4276 in Patients with Advanced HER2-Positive Breast or Gastric Cancer


05 Mar 2018


Proffered Paper Session 1


Mark Pegram


Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048


M. Pegram1, E. Hamilton2, A.R. Tan3, A.M. Storniolo4, N. Elgeioushi5, S. Marshall5, S. Abdullah5, M. Patel6

Author affiliations

  • 1 Department Of Medicine, Stanford Comprehensive Cancer Institute, CA 94305-545 - Stanford/US
  • 2 Florida Cancer Specialists/Sarah Cannon Research Institute, Nashville/US
  • 3 Levine Cancer Institute, Charlotte/US
  • 4 Indiana University Simon Cancer Center, Indianapolis/US
  • 5 MedImmune, Gaithersburg/US
  • 6 Florida Cancer Specialists, Sarasota/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 220

MEDI4276 is a HER2-bispecific antibody targeting two different epitopes on HER2, with site-specific conjugation via maleimidocaproyl linker to a potent tubulysin-based microtubule inhibitor. MEDI4276 demonstrates enhanced cellular internalization and cytolysis of HER2+ tumor cells in vitro, including T-DM1 resistant cells.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings